Uegaki Takashi, Taniguchi Fuminori, Nakamura Kazuomi, Osaki Mitsuhiko, Okada Futoshi, Yamamoto Osamu, Harada Tasuku
Department of Obstetrics and Gynecology, Tottori University Faculty of Medicine, 36-1 Nishi-cho, Yonago 683-8504, Japan.
Department of Obstetrics and Gynecology, Tottori University Faculty of Medicine, 36-1 Nishi-cho, Yonago 683-8504, Japan
Hum Reprod. 2015 Jan;30(1):149-58. doi: 10.1093/humrep/deu288. Epub 2014 Nov 5.
What is the role of the inhibitor of apoptosis proteins (IAPs) in human endometriotic tissues and a mouse model of endometriosis?
Four IAP proteins were expressed in endometriotic tissue indicating IAPs may be a key factor in the pathogenesis and progression of endometriosis.
Overexpression of IAPs protects against a number of proapoptotic stimuli. IAPs (c-IAP1, c-IAP2, XIAP and Survivin) are expressed in human ectopic endometrial stromal cells (ESCs) from ovarian endometriomas.
STUDY DESIGN, SIZE, DURATION: Forty-eight women with or without ovarian endometrioma are included in this study. BALB/c mice (n = 24) were used for the mouse endometriosis model. Mice with surgically induced endometriosis were treated with an IAP antagonist (BV6) for 4 weeks.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Human ectopic endometrial tissues from chocolate cysts and eutopic endometrial tissue were collected. ESCs were enzymatically isolated from these tissues. ESC proliferation was examined by 5-bromo-2'-deoxyuridine-enzyme-linked immunosorbent assay. IAPs expression in tissue derived from eutopic endometria and chocolate cysts was evaluated using real-time RT-PCR and immunohistochemistry. A homologous mouse endometriosis model was established by transplanting donor mouse uterine tissue into the abdominal cavities of recipient mice. After treating the mice with BV6 (i.p. 10 mg/ml), the extent of endometriosis-like lesions in mice was measured and proliferative activity assessed by Ki67 staining. All experiments were repeated a minimum of three times.
IAP (c-IAP1, c-IAP2, XIAP and Survivin) mRNA and protein in human ectopic endometrial tissues were expressed at higher levels than in eutopic endometrial tissues (P < 0.05). All four IAPs proteins were expressed in mouse endometriosis-like implants. BV6 inhibited BrdU incorporation of human ESCs (P < 0.05 versus control). BV6 also decreased the total number, weight, surface area and Ki67 positive cells in the endometriosis-like lesions in the mice (P < 0.05 versus control).
LIMITATIONS, REASONS FOR CAUTION: Endometriotic lesions were surgically induced in mice by transplanting mouse uterine tissue only, not human pathological endometriotic tissue. Furthermore, the effects of BV6 on human ESCs and mouse endometriosis-like lesions may differ between the species.
Our data support the hypothesis that IAPs are involved in the development of endometriosis, and therefore an inhibitor of IAPs has potential as a novel treatment for endometriosis.
STUDY FUNDING/COMPETING INTERESTS: This work was supported by KAKENHI (Japan Society for the Promotion of Science, Grant-in-Aid: to F.T.; 21592098 and to T.H.; 24659731) and Yamaguchi Endocrine Research Foundation. The authors have no conflicts of interest to disclose.
凋亡抑制蛋白(IAPs)在人类子宫内膜异位组织及子宫内膜异位症小鼠模型中起什么作用?
四种IAP蛋白在子宫内膜异位组织中表达,表明IAPs可能是子宫内膜异位症发病机制和进展中的关键因素。
IAPs的过表达可抵御多种促凋亡刺激。IAPs(细胞凋亡抑制蛋白1、细胞凋亡抑制蛋白2、X连锁凋亡抑制蛋白和生存素)在卵巢子宫内膜异位囊肿的人类异位子宫内膜间质细胞(ESCs)中表达。
研究设计、规模、持续时间:本研究纳入了48名有或无卵巢子宫内膜异位囊肿的女性。BALB/c小鼠(n = 24)用于构建子宫内膜异位症小鼠模型。对手术诱导的子宫内膜异位症小鼠用IAP拮抗剂(BV6)治疗4周。
参与者/材料、环境、方法:收集巧克力囊肿的人类异位子宫内膜组织和在位子宫内膜组织。从这些组织中酶解分离出ESCs。通过5-溴-2'-脱氧尿苷酶联免疫吸附测定法检测ESCs增殖。使用实时逆转录聚合酶链反应和免疫组织化学评估在位子宫内膜和巧克力囊肿来源组织中IAPs的表达。通过将供体小鼠子宫组织移植到受体小鼠腹腔中建立同源性小鼠子宫内膜异位症模型。用BV6(腹腔注射,10 mg/ml)处理小鼠后,测量小鼠子宫内膜异位样病变的范围,并通过Ki6细胞增殖抗原(Ki67)染色评估增殖活性。所有实验至少重复三次。
人类异位子宫内膜组织中IAP(细胞凋亡抑制蛋白1、细胞凋亡抑制蛋白2、X连锁凋亡抑制蛋白和生存素)的信使核糖核酸和蛋白质表达水平高于在位子宫内膜组织(P < 0.05)。所有四种IAP蛋白均在小鼠子宫内膜异位样移植物中表达。BV6抑制人类ESCs的5-溴-2'-脱氧尿苷掺入(与对照组相比,P < 0.05)。BV6还减少了小鼠子宫内膜异位样病变中的总数、重量、表面积和Ki67阳性细胞(与对照组相比,P < 0.05)。
局限性、谨慎的理由:仅通过移植小鼠子宫组织而非人类病理性子宫内膜异位组织在小鼠中手术诱导子宫内膜异位病变。此外,BV6对人类ESCs和小鼠子宫内膜异位样病变的影响在不同物种之间可能有所不同。
我们的数据支持IAPs参与子宫内膜异位症发展的假说,因此IAPs抑制剂有潜力成为子宫内膜异位症的一种新疗法。
研究资金/利益冲突:本研究得到了日本学术振兴会科研资助金(编号:给F.T.的21592098和给T.H.的24659731)以及山口内分泌研究基金会的支持。作者没有利益冲突需要披露。